Humana Stock And 2 Defensive Healthcare Picks For Uncertain Fed Rates

With the Federal Reserve’s July decision looming, interest rates, inflation targets, and political pressure on the central bank are all back in focus, and that can rattle even experienced investors. One way to respond is to look at large cap defensive stocks that may offer a steadier ride when policy signals are hard to read. This article breaks down how the current Fed debate over its 2% inflation target, its independence, and Chair Kevin Warsh’s guidance could affect three specific stocks from a defensive screener, and why each one may either deserve a closer look or a cautious distance right now.

Overview: Convatec Group is a London headquartered healthcare company that develops and sells medical products and technologies used to manage chronic and acute conditions, including advanced wound dressings, ostomy and continence care, and infusion sets for insulin and other therapies. Its products are supplied to hospitals, pharmacies and patients across Europe, North America and other international markets.

Operations: Convatec Group generates about $2.4b in revenue from the development, manufacture and sale of medical products and technologies, with key geographic exposure to the US, Denmark, the UK and other international markets.

Market Cap: £4.2b

Convatec Group stands out in this large cap defensive screen because it sits in a healthcare niche where demand for advanced wound care, ostomy and continence products is closely tied to chronic conditions rather than swings in economic activity, which can appeal when Fed policy is hard to read. Analysts describe the stock as trading well below estimated fair value, even as P/E sits above the European medical equipment average, which points to a mix of quality and pricing risk. High debt, US reimbursement exposure and an unstable dividend record mean this is not a simple “set and forget” idea, but the active product pipeline and margin focus give investors plenty to weigh up before deciding how it fits their own risk tolerance.

Convatec Group’s combination of a higher P/E, chronic care exposure and analyst claims of undervaluation suggests the market might be mispricing its risk-reward trade off. The 3 key rewards and 3 important warning signs could reveal what everyone else is missing.

Overview: Humana is a Louisville based health insurer that focuses on Medicare Advantage and prescription drug plans for seniors, complemented by specialty coverage such as dental, vision, life and disability insurance, and a growing CenterWell arm that runs senior primary care centers, home health and pharmacy services.

Operations: Humana generates about US$131.7b in revenue from its Insurance segment and US$23.5b from CenterWell, with total revenue of roughly US$137.3b coming from the United States after eliminations.

Market Cap: US$47.4b

Humana attracts attention in a period of Fed uncertainty because it sits squarely in essential healthcare, where Medicare funded coverage and senior care tend to be less sensitive to rate driven swings in consumer spending. At the same time, the stock still reflects tension between growth, valuation and risk. Analysts highlight revenue and earnings expectations supported by expanding CenterWell primary care and pharmacy services, while recent net margins are thin at 0.8% and returns on equity are modest, partly reflecting a large one off loss and reliance on external borrowing. For investors weighing whether the current P/E ratio, regulatory headwinds around Medicare Advantage and debt funding are adequately reflected in the price, Humana’s mix of perceived opportunity and risk may warrant closer examination before drawing a firm conclusion.

Humana’s thin margins and reliance on borrowing could be masking a very different story once future expectations are properly weighed, so review the analyst forecasts for Humana before a single assumption hardens into conviction

Overview: Cencora is a global pharmaceutical distributor that connects drug manufacturers with hospitals, pharmacies, clinics and animal health providers, while also offering services such as clinical trial support, data analytics, commercialization help and specialized logistics for complex therapies.

Operations: Cencora generates most of its revenue from U.S. Healthcare Solutions at about US$296.6b, with around US$31.9b from International Healthcare Solutions and smaller segment adjustments and eliminations.

Market Cap: US$59.4b

Cencora attracts attention in a Fed focused market because it sits at the heart of drug distribution, where demand for medications and specialty therapies tends to be steadier than consumer spending. Yet the stock still trades well below one DCF estimate of fair value. Earnings grew around 30% per year over five years, and recent buyback authorizations, a new CFO and digital investments such as inventory management tools point to a management team trying to use its scale more efficiently, even as net margins sit at just 0.8% and debt coverage by cash flow is tight. Regulatory pressure on drug pricing, thin margins on high volume products and international softness all matter, but the key question is whether Cencora’s mix of scale, specialty focus and capital discipline is being fully reflected in today’s price.

Cencora’s thin 0.8% margins and tight debt coverage could be masking how its scale and specialty focus really work together, so review the 4 key rewards and 1 important major warning sign to see what might be hiding in plain sight

The three stocks covered here are only a starting point, as the full Large-Cap Defensive Stocks screener has identified 11 more companies with equally compelling stories that could fit a more resilient core in your portfolio. It is worth seeing how they compare across sectors and geographies in the Large-Cap Defensive Stocks screener. Use Simply Wall St to identify and analyze the specific catalysts, risk flags and narratives that matter to you, so you can focus on the highest conviction ideas instead of sifting through noise.

Take Control of Your Investment Journey

If Convatec Group or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point.
Once you’ve made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.
Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.
By uncovering hidden catalysts and risks early, you’ll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond These Picks?

New ideas are moving fast and early entries can be gone before the crowd even notices. Spot fresh momentum while it matters and before it gets fully priced, then act while the opportunity is still available.

• Spot overlooked strength in companies with cleaner finances by scanning a curated list of solid balance sheet and fundamentals (20 results) that helps you separate durable businesses from those built on shaky foundations.
• Explore early breakout potential in cash generative miners using a focused 33 elite gold producer stocks that highlights producers with scale, staying power and room for the story to develop.
• Track rising momentum in overlooked automation leaders through a hand picked 34 robotics and automation stocks packed with companies building the machines and systems others may rely on in the future.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com